Apexian Pharmaceuticals Presents Findings at ASH Meeting Demonstrating APX3330 Impact on Inflammation and Leukemia?in Preclinical Models

INDIANAPOLIS–(BUSINESS WIRE)–Apexian Pharmaceuticals is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. Genetic mutations by themselves are rarely enough to flip the switch. Inflammation also plays a role. But, until now, the question of ?how? remained unanswered. Apexian Chief Science Officer Mark Kelley, PhD, and his colleagues presented their findings at the American Society of Hematology?s December 1, 2018 meeting in San Diego, California. When